Characterization of in vivo metabolites of WR319691, a novel compound with activity against Plasmodium falciparum

European Journal of Drug Metabolism and Pharmacokinetics

Volumn 36, Issue 3, 2011, Pages 151-158

  Milner, Erin ^a   Sousa, Jason ^a   Pybus, Brandon ^a   Melendez, Victor ^a   Gardner, Sean ^a   Grauer, Kristina ^a   Moon, Jay ^a   Carroll, Dustin ^a   Auschwitz, Jennifer ^a   Gettayacamin, Montip ^a   Lee, Patricia ^a   Leed, Susan ^a   McCalmont, William ^a   Norval, Suzanne ^a   Tungtaeng, Anchalee ^a   Zeng, Qiang ^a   Kozar, Michael ^a   Read, Kevin D ^a   Li, Qigui ^a   Dow, Geoffrey ^a  

^a WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

Author keywords

Brain levels; Malaria; Mefloquine; N dealkylated metabolites

Indexed keywords

ANTIMALARIAL AGENT; ANTISPOROZOAL AGENT; MEFLOQUINE; UNCLASSIFIED DRUG; WR 160972; WR 308245; WR 318973; WR 319670; WR 319691; WR 319707; QUINOLINE DERIVATIVE; WR319691;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIMALARIAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DEALKYLATION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG DETERMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG SCREENING; DRUG STRUCTURE; IN VIVO STUDY; MALARIA FALCIPARUM; MALE; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; PLASMODIUM FALCIPARUM; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; ANIMAL; BRAIN; DRUG EFFECT; LIVER; METABOLISM;

ANIMALS; ANTIMALARIALS; BRAIN; LIVER; MALE; MICE; PLASMODIUM FALCIPARUM; QUINOLINES;

EID: 84856403511     PISSN: 03787966     EISSN: 21070180     Source Type: Journal    
DOI: 10.1007/s13318-011-0047-8     Document Type: Article

References (11)

1. Briand V, Bottero J, Noël H, Masse V, Cordel H, Guerra J, Kossou H, Fayomi B, Ayemonna P, Fievet N, Massougbodji A, Cot M (2009) Intermittent treatment for the prevention of malaria during pregnancy in Benin: a randomized, open-label equivalence trial comparing sulfadoxine-pyrimethamine with mefloquine. J Infect Dis 200:991-1001
2. Cairns M, Gosling R, Carneiro I, Gesase S, Mosha JF, Hashim R, Kaur H, Lemnge M, Mosha FW, Greenwood B, Chandramohan D (2010) Duration of protection against clinical malaria provided by three regimens of intermittent preventive treatment in Tanzanian infants. PLoS One 5:e9467
3. Centers for Disease Control (2008) CDC health information for international travel. Elsevier, Atlanta Dow GS, Heady TN, Bhattacharjee AK, Caridha D, Gerena L, Gettayacamin M, Lanteri CA, Obaldia N 3rd, Roncal N, Shearer T, Smith PL, Tungtaeng A,Wolf L, Cabezas M, Yourick D, Smith KS (2006) Utility of alkylaminoquinolinyl methanols as new antimalarial drugs. Antimicrob Agents Chemother 50:4132-4143 (Pubitemid 44865158)
4. Dow GS, Magill AJ, Ohrt C (2008) Clinical development of new prophylactic antimalarial drugs after the 5th Amendment to the Declaration of Helsinki. Ther Clin Risk Manag 4:803-819
5. Dow G, Milner E, Bhonsle J, Caridha D, Gardner S, Gerena L, Kozar M, Lanteri C, Mannila A, McCalmont W, Melendez V, Moon J, Read K, Norval S, Roncal N, Shackleford D, Sousa J, Stouten J, White K, Zeng Q, Charman S (2011) Central nervous system (CNS) exposure of next generation quinoline methanols is reduced relative to mefloquine after intravenous (IV) dosing in mice. Malar J 10:150
6. Gosling RD, Gesase S, Mosha JF, Carneiro I, Hashim R, Lemnge M, Mosha FW, Greenwood B, Chandramohan D (2009) Protective efficacy and safety of three antimalarial regimens for intermittent preventive treatment for malaria in infants: a randomized, double-blind, placebo-controlled trial. Lancet 374:1521-1532
7. Kalvass JC, Maurer TS (2002) Influence of non-specific brain and plasma binding on CNS exposure: implications for rational drug discovery. Biopharmaceutics and Drug Disp. 23:327-338 (Pubitemid 36124162)
8. McGready R (2010) Intermittent preventive treatment of infants with mefloquine reduces risk of clinical malaria in areas of moderate malaria transmission and high resistance to sulphadoxinepyrimethamine, but safety and tolerability issues need consideration. Evid Based Med. 15:71-72
9. Milner E, McCalmont W, Bhonsle J, Caridha D, Carroll D, Gardner S, Gerena L, Gettayacamin M, Lanteri C, Luong T, Melendez V, Moon J, Roncal N, Sousa J, Tungtaeng A, Wipf P, Dow G (2010a) Structure-activity relationships amongst 4-position quinoline methanol antimalarials that inhibit the growth of drug sensitive and resistant strains of Plasmodium falciparum. Bioorg Med Chem Lett 20:1347-1351
10. Milner E, McCalmont W, Bhonsle J, Caridha D, Cobar J, Gardner S, Gerena L, Goodine D, Lanteri C, Melendez V, Roncal N, Sousa J, Wipf P, Dow GS (2010b) Anti-malarial activity of a nonpiperidine library of next-generation quinoline methanols. Malar J 11:51
11. Summerfield SG, Read K, Begley DJ, Obradovic T, Hidalgo IJ, Coggon S, Lewis AV, Porter RA, Jeffrey P (2007) Central nervous system drug disposition: the relationship between in situ brain permeability and brain free fraction. JPET 322:205-213 (Pubitemid 46956363)